Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition
01–04 December 2018 | San Diego, CA

ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition
01–04 December 2018 | San Diego, CA

Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

CLL

View all
Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL
Stephan Stilgenbauer
Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results
Jennifer Woyach

Multiple Myeloma

View all
Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients
Ola Landgren
Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar

Waldenström’s

View all
Association between depth of response and survival in Waldenström’s
Jonas Paludo
Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s
Jonas Paludo

AML

View all
1:57
An update on AMG 330: can BiTEs be as successful in AML as ALL?
Marion Subklewe • 2 Dec 2018
1:15
E-selectin antagonist uproleselan for R/R AML: efficacy and safety data
Daniel DeAngelo • 2 Dec 2018

Lymphoma

View all
5:51
Updated JULIET results for tisagenlecleucel in DLBCL
Richard Thomas Maziarz • 1 Dec 2018
1:23
R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL
Ian Flinn • 2 Dec 2018

ALL

View all
1:14
Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma
Jordan Gauthier • 2 Dec 2018
6:20
Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL
Stephan Grupp • 4 Dec 2018

Sickle Cell Disease & β-Thalassemia

View all
7:08
BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden
Maria Domenica Cappellini
7:37
Opioid use in sickle cell is not associated with in-hospital mortality in the US
Oladimeji Akinola Akinboro • 2 Dec 2018

Trial Updates

View all
Updates from MURANO for CLL: time-limited VenR & impact of MRD
John Seymour
4:40
Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook
Viola Poeschel • 3 Dec 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals